Authorized purpose: Notification-only, parallel workflow tool for hospital networks and trained clinicians that analyzes acute non-contrast brain CT and communicates suspected intracranial hemorrhage to a neurovascular or neurosurgical specialist for review.
Clinical role
Parallel specialist-notification and communication workflow; it prioritizes review without marking or altering original images and is not a diagnostic or full-patient-evaluation substitute.
Keep in mind: Mobile previews may be compressed and are informational only, not diagnostic beyond notification. Clinicians must view non-compressed images on a diagnostic viewer, perform full patient evaluation, and discuss care with the treating physician; the device must not be relied on to make or confirm a diagnosis.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Notification-only, parallel workflow tool for hospital networks and trained clinicians that analyzes acute non-contrast brain CT and communicates suspected intracranial hemorrhage to a neurovascular or neurosurgical specialist for review.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head/brain; suspected intracranial hemorrhage. Input: Acute-setting non-contrast CT images of the brain from DICOM-compliant imaging devices and modalities.
Who uses it?Intended users: Hospital networks and trained clinicians; notifications are directed to neurovascular or neurosurgical specialists, with treating-physician discussion required before care decisions.
What does the software produce?Output: Notification of suspected intracranial hemorrhage to a neurovascular or neurosurgical specialist, push/toggle notifications, patient/study/image DICOM information, and a compressed non-diagnostic CT preview through the Viz VIEW mobile application.
What is its most important limitation?Key limitation: Mobile previews may be compressed and are informational only, not diagnostic beyond notification. Clinicians must view non-compressed images on a diagnostic viewer, perform full patient evaluation, and discuss care with the treating physician; the device must not be relied on to make or confirm a diagnosis.
Clinical takeaway. Clinical role: Notification-only, parallel workflow tool for hospital networks and trained clinicians that analyzes acute non-contrast brain CT and communicates suspected intracranial hemorrhage to a neurovascular or neurosurgical specialist for review.
Evidence takeaway. Evidence from the reviewed source record: FDA K210209 reports 387 NCCT studies from two U.S. clinical sites, with approximately 50.6% ICH-positive and 49.4% ICH-negative cases; trained neuroradiologists established ground truth. Overall sensitivity was 95% (95% CI 91%-98%) and specificity 96% (95% CI 92%-98%), meeting the prespecified 80% goals. AUC was 0.97, and mean alerting time was 0.49+/-0.08 minutes versus 18.3+/-14.2 minutes for standard-of-care notification; AUC and latency are separate endpoints. Subgroup estimates were reported by site, age, gender, hemorrhage subtype, slice thickness, scanner manufacturer/model, volume threshold, and reconstruction method.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Notification-only, parallel workflow tool for hospital networks and trained clinicians that analyzes acute non-contrast brain CT and communicates suspected intracranial hemorrhage to a neurovascular or neurosurgical specialist for review.
Parallel specialist-notification and communication workflow; it prioritizes review without marking or altering original images and is not a diagnostic or full-patient-evaluation substitute.
Notification of suspected intracranial hemorrhage to a neurovascular or neurosurgical specialist, push/toggle notifications, patient/study/image DICOM information, and a compressed non-diagnostic CT preview through the Viz VIEW mobile application.
Acute hospital-network workflow parallel to standard-of-care interpretation; image analysis is hosted on Viz.ai servers and notifications are available through the mobile module.
Hospital networks and trained clinicians; notifications are directed to neurovascular or neurosurgical specialists, with treating-physician discussion required before care decisions.
Mobile previews may be compressed and are informational only, not diagnostic beyond notification. Clinicians must view non-compressed images on a diagnostic viewer, perform full patient evaluation, and discuss care with the treating physician; the device must not be relied on to make or confirm a diagnosis.
FDA K210209 reports 387 NCCT studies from two U.S. clinical sites, with approximately 50.6% ICH-positive and 49.4% ICH-negative cases; trained neuroradiologists established ground truth. Overall sensitivity was 95% (95% CI 91%-98%) and specificity 96% (95% CI 92%-98%), meeting the prespecified 80% goals. AUC was 0.97, and mean alerting time was 0.49+/-0.08 minutes versus 18.3+/-14.2 minutes for standard-of-care notification; AUC and latency are separate endpoints. Subgroup estimates were reported by site, age, gender, hemorrhage subtype, slice thickness, scanner manufacturer/model, volume threshold, and reconstruction method.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K210209 reports 387 NCCT studies from two U.S. clinical sites, with approximately 50.6% ICH-positive and 49.4% ICH-negative cases; trained neuroradiologists established ground truth. Overall sensitivity was 95% (95% CI 91%-98%) and specificity 96% (95% CI 92%-98%), meeting the prespecified 80% goals. AUC was 0.97, and mean alerting time was 0.49+/-0.08 minutes versus 18.3+/-14.2 minutes for standard-of-care notification; AUC and latency are separate endpoints. Subgroup estimates were reported by site, age, gender, hemorrhage subtype, slice thickness, scanner manufacturer/model, volume threshold, and reconstruction method.
Overall Viz ICH sensitivity: 95% (95% CI 91%-98%) across 387 NCCT studies from two U.S. sites, with ground truth established by trained neuroradiologists.
FDA source
Exact FDA submission
Checked 2026-09-09
The 80% figure is the prespecified goal; AUC, alert latency, and subgroup sensitivity are separate endpoints.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Viz ICH regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K210209
Samplen=387
Sites2
IndependenceIndependence not established
K210209
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K210209. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Acute-setting non-contrast CT images of the brain from DICOM-compliant imaging devices and modalities.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The image-analysis algorithm is hosted on Viz.ai servers and receives DICOM studies forwarded from CT scanners; the Viz VIEW mobile module provides notifications and non-diagnostic previews. The packet does not establish a specific PACS/RIS/EHR route, interface version, or current commercial configuration.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the Viz ICH image analysis algorithm as hosted on Viz.ai's servers, which receive NCCT images forwarded from CT scanners, with notifications and non-diagnostic image viewing through the Viz VIEW mobile application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The Viz ICH Image Analysis Algorithm is hosted on Viz.ai’s servers and analyzes applicable stroke-protocoled NCCT images of the head that are acquired on CT scanners and are forwarded to Viz.ai servers." … "The Viz ICH mobile notification software module is implemented into Viz.ai’s non-diagnostic DICOM image viewer, Viz VIEW, which displays CT scans that are sent to Viz.ai’s servers.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Notification of suspected intracranial hemorrhage to a neurovascular or neurosurgical specialist, push/toggle notifications, patient/study/image DICOM information, and a compressed non-diagnostic CT preview through the Viz VIEW mobile application.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Notification of suspected intracranial hemorrhage to a neurovascular or neurosurgical specialist, push/toggle notifications, patient/study/image DICOM information, and a compressed non-diagnostic CT preview through the Viz VIEW mobile application.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the Viz ICH image analysis algorithm as hosted on Viz.ai's servers, which receive NCCT images forwarded from CT scanners, with notifications and non-diagnostic image viewing through the Viz VIEW mobile application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The Viz ICH Image Analysis Algorithm is hosted on Viz.ai’s servers and analyzes applicable stroke-protocoled NCCT images of the head that are acquired on CT scanners and are forwarded to Viz.ai servers." … "The Viz ICH mobile notification software module is implemented into Viz.ai’s non-diagnostic DICOM image viewer, Viz VIEW, which displays CT scans that are sent to Viz.ai’s servers.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The image-analysis algorithm is hosted on Viz.ai servers and receives DICOM studies forwarded from CT scanners; the Viz VIEW mobile module provides notifications and non-diagnostic previews. The packet does not establish a specific PACS/RIS/EHR route, interface version, or current commercial configuration.
Viz.ai's own news releases say the Viz.ai One platform completed a SOC 2 Type II + HIPAA audit (announced 2024-02-26) and received ISO 27001:2022 plus six other ISO certificates (announced 2024-07-10). These are vendor announcements; the report and certificates were not read, and certificate dates may have lapsed or renewed since.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Viz.ai's trust center states that its assurance program includes continuously monitored controls, SOC 2 Type II coverage that includes the availability criterion for Viz.ai production systems and supporting infrastructure, ISO 22301 business continuity certification to ensure uninterrupted clinical workflows, and ISO 27035 incident management certification.
Vendor-wide
Checked 2026-10-27
Vendor statements, not attestations. Certificates and audit reports were not read; the trust center names Viz.ai generally and does not scope these commitments to any specific product release; exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
2Screened PubMed leads
2Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 2 PubMed and 2 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 2 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K210209 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.
Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Authorized purpose: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.
Modality
CT/CTA
Anatomy
Brain/head, including intracranial ICA and M1 for LVO and intracranial hemorrhage findings
Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.